Open access
Open access
Powered by Google Translator Translator

HIV

Cohort Study | Association of HIV infection and incident abdominal aortic aneurysm

31 May, 2023 | 13:55h | UTC

Association of HIV Infection and Incident Abdominal Aortic Aneurysm Among 143 001 Veterans – Journal of the American Heart Association

 


Phase 2 RCT | Single high-dose L-AmB shows comparable efficacy to standard treatment in HIV/AIDS-related histoplasmosis

29 May, 2023 | 10:41h | UTC

Single High-dose of Liposomal Amphotericin B in HIV/AIDS-related Disseminated Histoplasmosis: a Randomized Trial – Clinical Infectious Diseases

See also: Visual Abstract

 


A humorous peek into HIV research papers: a quick guide

18 May, 2023 | 13:46h | UTC

Types of HIV Papers — A Quick Guide – HIV and Observations

 

Commentary on Twitter

 


RCT | ART intensification shows no benefit in treating HIV-associated neurocognitive impairment

18 May, 2023 | 13:31h | UTC

Antiretroviral Therapy Intensification for Neurocognitive Impairment in HIV – Clinical Infectious Diseases

 


Cohort Study | Infection-unrelated cancers are increasingly more common than infection-related cancers among individuals with HIV

2 May, 2023 | 13:32h | UTC

Age and Cancer Incidence in 5.2 Million People With Human Immunodeficiency Virus (HIV): The South African HIV Cancer Match Study – Clinical Infectious Diseases (free for a limited period)

Commentary: Infection-Unrelated Cancers Predominant Among Older Adults With HIV – Cancer Therapy Advisor

 

Commentary on Twitter

 


Podcast | HIV in primary care

6 Apr, 2023 | 13:13h | UTC

#388 HIV in Primary Care with Dr. Jonathan J. “JJ” Nunez MD – The Curbsiders

 


Cohort Study | Barriers to starting direct-acting antiviral treatment despite access for HIV & hepatitis C patients

6 Apr, 2023 | 13:09h | UTC

Reasons for not commencing direct-acting antiviral treatment despite unrestricted access for individuals with HIV and hepatitis C virus: a multinational, prospective cohort study – The Lancet Public Health

Invited Commentary: The road to hepatitis C virus elimination – The Lancet Public Health

 


Long-acting injectable antiretroviral therapy: will it change the future of HIV treatment?

30 Mar, 2023 | 13:49h | UTC

Long-acting injectable antiretroviral therapy: will it change the future of HIV treatment? – Therapeutic Advances in Infectious Disease

 


M-A | Factors associated with post-treatment control of viral load in HIV-infected patients

29 Mar, 2023 | 12:56h | UTC

Factors Associated with Post-treatment Control of Viral Load in HIV-Infected Patients: A Systematic Review and Meta-analysis – International Journal of Infectious Diseases

 


Updated recommendations for the use of antiretroviral drugs during pregnancy and interventions to reduce perinatal HIV transmission

15 Mar, 2023 | 15:22h | UTC

Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States – Department of Health and Human Services

Commentary: Antiretroviral Therapy During Pregnancy and Interventions to Reduce Perinatal Transmission: 2023 Recommendations – Journal Watch

 


RCT | Long-term effects of early antiretroviral therapy initiation in HIV infection highlight the importance of early treatment

1 Mar, 2023 | 14:12h | UTC

Summary: The article discusses the long-term results of the Strategic Timing of AntiRetroviral Treatment (START) trial, which aimed to determine the effects of early initiation of antiretroviral therapy (ART) for individuals with HIV and CD4+ counts above 500 cells/mm3 compared to those who deferred treatment until their CD4+ count was below 350 cells/mm3. The trial found that immediate ART initiation reduced the risk of AIDS and serious non-AIDS (SNA) conditions compared to deferred treatment. The study’s long-term results also found that a persistent excess risk of AIDS and SNA conditions remained even after ART was initiated in those who initially deferred treatment. The study highlights the importance of early diagnosis and prompt initiation of ART for individuals with HIV.

Article: Long-Term Benefits from Early Antiretroviral Therapy Initiation in HIV Infection – NEJM Evidence

Original Study: Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection – New England Journal of Medicine

 


M-A | Adverse perinatal outcomes associated with antiretroviral therapy in women living with HIV

27 Feb, 2023 | 12:48h | UTC

Adverse perinatal outcomes associated with antiretroviral therapy in women living with HIV: A systematic review and meta-analysis – Frontiers in Medicine

 


Mpox outbreak in advanced HIV cases | Global case series reveals higher mortality and clinical complications

23 Feb, 2023 | 13:44h | UTC

Summary: This article discusses a case series investigating monkeypox (mpox) in people with HIV and low CD4 cell counts. The mpox outbreak in 2022 has affected a significant percentage of people living with HIV, and data suggest worse clinical outcomes and higher mortality in those with more advanced HIV. The case series includes data from 382 confirmed mpox cases in people living with HIV from 19 countries. The individuals included were predominantly cisgender men, with a median age of 35. Most individuals were adherent to antiretroviral therapy, and the median CD4 count was 211 cells per mm3. Severe complications were more common in those with lower CD4 cell counts, including necrotizing skin lesions, lung involvement, secondary infections, and sepsis. Approximately 28% of individuals were hospitalized, and 25% of those hospitalized died. All deaths occurred in people with CD4 counts of less than 200 cells per mm3. The study reinforces the importance of HIV and CD4 testing in mpox cases, prioritization of preventive mpox vaccination in people with HIV and a CD4 cell count of less than 200 cells per mm3, and the use of potential mpox antivirals where available. The authors suggest that a severe, disseminated, and necrotizing form of mpox should be considered an AIDS-defining condition in CDC and WHO HIV disease classifications. Clinicians should also be aware that starting antiretroviral therapy in people with advanced HIV and mpox could contribute to deterioration and possible death, possibly as part of an immune reconstitution syndrome.

Article: Mpox in people with advanced HIV infection: a global case series – The Lancet (free registration required)

News Release: Clinicians identify severe form of mpox with high mortality in people with advanced HIV – Queen Mary University of London

Commentaries:

Expert comment – Severe form of mpox identified in people with advanced HIV – London School of Hygiene & Tropical Medicine

Mpox: Clinicians identify severe form with high mortality in advanced HIV patients – The BMJ

 

Commentary from the author on Twitter (thread – click for more)

 


152-week results of a RCT | Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection

23 Feb, 2023 | 13:16h | UTC

Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection: 152-week results from ATLAS-2M, a randomized, open-label, Phase 3b, noninferiority study – Clinical Infectious Diseases

 


Late diagnosis of HIV: an updated consensus definition

14 Feb, 2023 | 10:49h | UTC

Late diagnosis of HIV: An updated consensus definition – HIV Medicine

 


RCT | Pregnancy and neonatal safety of PrEP for HIV prevention initiated during pregnancy vs. afterwards

9 Feb, 2023 | 13:55h | UTC

Pregnancy and neonatal safety outcomes of timing of initiation of daily oral tenofovir disoproxil fumarate and emtricitabine pre-exposure prophylaxis for HIV prevention (CAP016): an open-label, randomised, non-inferiority trial – The Lancet HIV (link to abstract – $ for full-text)

 


Update guidelines for women with HIV who are virally suppressed incorporate breastfeeding their infants as a viable option

6 Feb, 2023 | 13:40h | UTC

Update to Clinical Guidelines for Infant Feeding Supports Shared Decision Making: Clarifying Breastfeeding Guidance for People with HIV – HIV.gov

 

Commentary on Twitter

 


M-A | Revisiting the evidence base for modern-day practice of the treatment of toxoplasmic encephalitis

27 Jan, 2023 | 12:14h | UTC

Revisiting the Evidence Base for Modern-Day Practice of the Treatment of Toxoplasmic Encephalitis: A Systematic Review and Meta-Analysis – Clinical Infectious Diseases

 


Phase 2 RCT | Lenacapavir every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV

27 Jan, 2023 | 12:00h | UTC

Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial – The Lancet HIV (link to abstract – $ for full-text)

 


BHIVA guidelines on antiretroviral treatment for adults living with HIV-1 2022.

15 Dec, 2022 | 13:52h | UTC

BHIVA guidelines on antiretroviral treatment for adults living with HIV-1 2022 – HIV Medicine

Related: Consensus Recommendations | Antiretroviral drugs for treatment and prevention of HIV infection in adults.

 


Consensus Recommendations | Antiretroviral drugs for treatment and prevention of HIV infection in adults.

2 Dec, 2022 | 14:45h | UTC

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults2022 Recommendations of the International Antiviral Society–USA Panel – JAMA (free for a limited period)

Invited Commentary: Ending the HIV Epidemic: We Have the Tools, Do We Have the Will? – JAMA (free for a limited period)

Author Interview: Advances in Treatment and Prevention of HIV – JAMA

 


How applicable is the single-dose AMBITION regimen for HIV-associated cryptococcal meningitis to high-income settings?

29 Sep, 2022 | 13:26h | UTC

How applicable is the single-dose AMBITION regimen for HIV-associated cryptococcal meningitis to high-income settings? – Clinical Infectious Diseases

 

Commentary on Twitter

Under a https://creativecommons.org/licenses/by/4.0/ license

 


Global, regional, and national burdens of HIV and other sexually transmitted infections in adolescents and young adults aged 10–24 years from 1990 to 2019: a trend analysis based on the Global Burden of Disease Study 2019.

16 Sep, 2022 | 12:50h | UTC

Global, regional, and national burdens of HIV and other sexually transmitted infections in adolescents and young adults aged 10–24 years from 1990 to 2019: a trend analysis based on the Global Burden of Disease Study 2019 – The Lancet Child & Adolescent Health (link to abstract – $ for full-text)

 

Commentary on Twitter

 


Systematic Review | Association of HIV infection with cardiovascular pathology based on advanced cardiovascular imaging.

15 Sep, 2022 | 13:02h | UTC

Association of HIV Infection With Cardiovascular Pathology Based on Advanced Cardiovascular Imaging: A Systematic Review – JAMA (free for a limited period)

Editorial: HIV, Subclinical Cardiovascular Disease, and Clinical Progression: Insights From Immunologic Heterogeneity – JAMA (free for a limited period)

 


Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomized ODYSSEY trial.

8 Sep, 2022 | 14:33h | UTC

Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial – The Lancet HIV

 

Commentary on Twitter

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts US$ 7.00/month

No spam, just news.